financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Upgrades Opinion On Shares Of Qualcomm Incorporated To Buy From Hold
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Upgrades Opinion On Shares Of Qualcomm Incorporated To Buy From Hold
May 1, 2024 10:16 PM

12:50 AM EDT, 05/02/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We up our 12-month target to $200 from $155 on a revised P/E of 17.8x our CY 25 EPS view of $11.21, within our peer universe but above historical. We raise our FY 24 (Sep.) EPS to $9.92 from $9.66 and FY 25 to $10.91 from $10.48. QCOM posts Mar-Q EPS of $2.44 vs. $2.15, beating the $2.32 consensus. Sales rose a paltry 1% but exceeded expectations. Despite concerns about iPhone unit growth, the trajectory of global handset units is improving (flat to up in CY 24) with 5G phones to grow by 10%. We do think QCOM is benefiting from better China demand, with premium Android devices selling well, while the ramp of Windows AI PCs represents a new growth opportunity. We also like QCOM's growing automotive pipeline ($45B; up from $30B in Sep. '22), with auto to generate +$4B in revenue annually in FY 26. Our upgrade reflects a growing TAM (AI PCs, smartphone content/share gains, autonomous cars, new IoT/industrial uses) that will offer sales diversification as we view QCOM as an on-device AI winner for the long haul.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
May 8, 2024
Treating America's obesity epidemic is turning into big business. Two pharmaceutical companies, Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) , are leading the weight-loss revolution with a new class of drugs known as GLP-1 agonists. Surging revenue and growing excitement has led some analysts to compare the success of GLP-1 drugs in the health and wellness...
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Trade Desk, Inc.
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Trade Desk, Inc.
May 8, 2024
12:45 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target at $100, on a P/E of 53.5x our '25 view, above peers but within its 10-year historical forward average. We keep our above consensus '24...
Research Alert: CFRA Lowers Opinion On Shares Of United Parks & Resorts Inc. To Hold From Buy
Research Alert: CFRA Lowers Opinion On Shares Of United Parks & Resorts Inc. To Hold From Buy
May 8, 2024
02:35 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target to $56 from $61, on 2024 EV/EBITDA of 7.3x, near the low-end of PRKS's long-term trading range of 7x-12x. We lift our 2024 EPS to...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings Plc
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings Plc
May 9, 2024
08:05 AM EDT, 05/09/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We adjust our 12-month target to $120 from $140, on a lower revised peer-premium P/E of 64.8x our CY 25 EPS estimate, warranted given our view of growth prospects. We...
Copyright 2023-2026 - www.financetom.com All Rights Reserved